Solcoseryl-enriched biodegradable diplene membrane for lower eyelid reconstruction: A novel bioactive approach

Background

The full-thickness excision of malignant lower-eyelid tumors, particularly those with posterior lamellar involvement, presents a reconstructive challenge. Traditional grafts often have limitations, prompting interest in biocompatible alternatives, such as biodegradable diplene membranes. This study introduces a novel modification to the standard protocol: the use of diplene membranes enriched with Solcoseryl, a metabolically active agent that enhances angiogenesis, reduces inflammation, and accelerates epithelialization.

Methods

Twenty-seven patients (mean age, 68.96 ​± ​8.09 years) with histologically confirmed malignant lower-eyelid tumors underwent reconstruction using diplene membranes combined with Solcoseryl. The outcomes were compared with those of a previously reported cohort treated with Diplene alone. The follow-up period ranged from 3 to 12 months.

Results

All patients achieved successful restoration of eyelid support with high aesthetic satisfaction. The Solcoseryl group demonstrated significantly faster epithelialization (mean 9.8 ​± ​1.2 days), improved microcirculatory parameters, and no serious complications. Minor hematomas occurred in two cases (7.4%).

Conclusion

The modified Diplene–Solcoseryl membrane enhanced wound healing and biocompatibility during lower-eyelid reconstruction by transforming the membrane into a bioactive scaffold. This innovation offers superior functional and aesthetic outcomes compared to standard diplene use and represents a significant advancement in oculoplastic and oncological reconstructive surgery.